-
Jan 17, 2025 | 
bmcpsychology.biomedcentral.com | Gustave Roussy
This cross-sectional study, carried out on a large sample of BCSs, made it possible to determine the values of the different domains of the PTG. The average of the total PTG score among the Seintinelles was 60.01 ± 18.11.
-
Dec 6, 2024 | 
link.springer.com | Gustave Roussy
AbstractDietary macronutrients significantly impact cardiometabolic health, yet research often focuses on individual macronutrient relationships. This study aimed to explore the associations between dietary macronutrient composition and cardiometabolic health. This study included 33,681 US adults (49.7 ± 18.3 years; 52.5% female) from the National Health and Nutrition Examination Survey during 1999–2014.
-
Jun 3, 2024 | 
trialbulletin.com | Gustave Roussy
OverviewThe goal of this clinical trial is to assess safety of pan-metastases directed SBRT combined
with ATRA and the lympho-protective efficacy of ATRA upon radiation-induced lymphopenia.
This is a French bicentric, open label, phase I/II clinical study that will comprise two
parts. Part I will evaluate the safety of the combination based on a single-arm safety run
design, while Part II will be randomized (ratio 1:1) and will study SBRT with or without
ATRA.
-
May 20, 2024 | 
link.springer.com | Gustave Roussy
The majority of patients with cancers of unknown primary have unfavourable outcomes when they receive empirical chemotherapy. The shift towards using precision medicine-based treatment strategies involves two options: tissue-agnostic or site-specific approaches. Here, we reflect on how cytology-based deep learning tools can be leveraged in these approaches. This is a preview of subscription content, to check access.
-
May 17, 2024 | 
ashpublications.org | Johns Hopkins |Daniel Howard |Gustave Roussy
This content is only available as a PDF.
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
-
May 7, 2024 | 
trialbulletin.com | Gustave Roussy
OverviewIndication : Adult patients with intermediate low or mid rectal adenocarcinoma to be treated
with total neoadjuvant therapy (TNT) potentially eligible for rectal preservation.
Primary objective is to assess efficacy of contact X-ray brachytherapy (CXB) in addition to
TNT in order to increase survival with organ preservation (OP), in selected intermediate risk
group of rectal adenocarcinomas (size from 3.5 to 6 cm, cT2N1 or T3N0-1, M0).
-
Apr 20, 2024 | 
link.springer.com | Cardiovascular Diseases |Metabolic Diseases |Aix Marseille |Gustave Roussy
Correction to: Diabetes Ther (2024) 15:1349–1360 https://doi.org/10.1007/s13300-024-01577-8In the original article, the figure 1 caption was published incorrectly as Adjusted Kaplan–Meier survival curves for the persistence with basal insulin therapy in the newly treated patients (T1DM right curves, T2DM left curves). The correct caption is Adjusted Kaplan–Meier survival curves for the persistence with basal insulin therapy in the newly treated patients (T1DM left curves, T2DM right curves).
-
Apr 19, 2024 | 
link.springer.com | Cardiovascular Diseases |Metabolic Diseases |Aix Marseille |Gustave Roussy
AbstractSecond-generation basal insulins like glargine 300 U/mL (Gla-300) have a longer duration of action and less daily fluctuation and interday variability than first-generation ones, such as glargine 100 U/mL (Gla-100). The EF-BI study, a nationwide observational, retrospective study, was designed to compare persistence, acute care complications, and healthcare costs associated with the initiation of such basal insulins (BI) in a real-life setting in France.
-
Apr 11, 2024 | 
jamanetwork.com | Antonin Levy |Gustave Roussy |Therapeutic Innovations |Faculté de Médecine
Local Immunoradiotherapy in Patients With Metastatic Soft-Tissue Sarcoma TLR4 and Radiotherapy for Metastatic Soft Tissue Sarcoma Yongwoo David Seo, MD; Hailing Lu, MD, PhD; Graeme Black, BS; Kimberly Smythe, BS; Yuexin Yu, PhD; Cynthia Hsu, BS; Juliana Ng, BS; Pedro Hermida de Viveiros, MD; E. Houston Warren, MD, PhD; Brett A. Schroeder, MD; Ryan B. O’Malley, MD; Lee D. Cranmer, MD, PhD; Elizabeth T. Loggers, MD, PhD; Michael J. Wagner, MD; Lynn Bonham, PhD; Venu G.
-
Mar 22, 2024 | 
molecular-cancer.biomedcentral.com | Gustave Roussy |Université Paris Saclay |Le Kremlin-Bicêtre |Institut Bergonié
In this international, multi-center single-arm phase 2 trial, we enrolled different cohorts of patients including advanced CRC, renal cell carcinoma, non-small cell lung cancer (NSCLC) and sarcomas who had at least 1) one lesion eligible for SBRT and 2) one unirradiated lesion, both measurable by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
